BC Innovations | Nov 11, 2010
Targets & Mechanisms

Going APOA1 in cancer

Researchers at the University of California, Los Angeles and colleagues have shown that apolipoprotein A-1 , the major component of high-density lipoprotein, could have a therapeutic effect in ovarian cancer. 1 Resverlogix Corp. , a biotech with...
BC Week In Review | Feb 15, 2010
Company News

Artery Therapeutics, Roche deal

The companies will co-develop Artery's apolipoprotein A-1 (APOA1) peptide mimetics. The deal includes Artery's lead, AT5261 , which is in preclinical testing to treat atherosclerosis and prevent cardiovascular events in patients who have suffered a heart...
BC Extra | Feb 12, 2010
Company News

Roche, Artery in APOA1 deal

Artery Therapeutics Inc. (Danville, Calif.) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to co-develop Artery's apolipoprotein A-1 (APOA1) peptide mimetics. The deal includes Artery's lead, AT5261, which is in preclinical testing to treat atherosclerosis and prevent cardiovascular...
Items per page:
1 - 3 of 3